
Opinion|Videos|January 15, 2025
Additional Safety Considerations With PBC Treatments
Panelists discuss how managing primary biliary cholangitis (PBC) in women of childbearing age requires careful consideration of pregnancy risk categories for different medications, with UDCA being the safest option during pregnancy, while second-line therapies require strict contraception and careful monitoring of hormone interactions to ensure optimal safety and efficacy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How should clinicians approach fetal toxicity risks with PBC treatments, especially when managing women of childbearing age, and what precautions are recommended?
- Explain the relevance of the interaction between PBC therapies and hormone replacement therapy. How should these interactions be managed to ensure patient safety?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ban Synthetic 7-OH: Natural Leaf Kratom Presents No Major Health Risk
2
Is Berberine Nature’s GLP-1?
3
Pharmacists Key to Counseling and Monitoring Patients Transitioning to Low-Sodium Oxybate
4
Incidence of VAIs in Patients With Chronic Kidney Disease on Dialysis Relatively Low
5













































































































































































































